Literature DB >> 31559417

Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study.

William T Clarke1, Konstantinos Papamichael1, Niels Vande Casteele2, Katharine A Germansky1, Joseph D Feuerstein1, Gil Y Melmed3, Corey A Siegel4, Peter M Irving5, Adam S Cheifetz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31559417     DOI： 10.1093/ibd/izz202

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  6 in total

Review 1.  Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review.

Authors:  Kyungah Suh; Isaac Kyei; David S Hage
Journal:  J Sep Sci       Date:  2022-03-10       Impact factor: 3.614

Review 2.  Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider.

Authors:  Charlotte Krieckaert; Borja Hernández-Breijo; Johanna Elin Gehin; Guillaume le Mélédo; Alejandro Balsa; Meghna Jani; Denis Mulleman; Victoria Navarro-Compan; Gertjan Wolbink; John Isaac; Astrid van Tubergen
Journal:  RMD Open       Date:  2022-06

Review 3.  Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases.

Authors:  Konstantinos Papamichael; William T Clarke; Niels Vande Casteele; Katharine A Germansky; Joseph D Feuerstein; Gil Y Melmed; Corey A Siegel; Peter M Irving; Adam S Cheifetz
Journal:  Clin Gastroenterol Hepatol       Date:  2020-03-05       Impact factor: 11.382

4.  Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.

Authors:  Ruben J Colman; Yi-Ting Tsai; Kimberly Jackson; Brendan M Boyle; Joshua D Noe; Jeffrey S Hyams; Geert R A M D'Haens; Johan van Limbergen; Michael J Rosen; Lee A Denson; Phillip Minar
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 7.290

Review 5.  Chronic recurrent multifocal osteomyelitis. A narrative and pictorial review.

Authors:  Consolato M Sergi; Elka Miller; Dina El Demellawy; Fan Shen; Mingyong Zhang
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

Review 6.  Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.

Authors:  Niels Vande Casteele; Brian G Feagan; Douglas C Wolf; Anca Pop; Mohamed Yassine; Sara N Horst; Timothy E Ritter; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2021-07-27       Impact factor: 5.325
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.